FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling

Media coverage

• Title	FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling
  Media name/outlet	PR Newswire
  Country	United States
  Date	10/11/18
  Persons	Antonio R Anzueto

• Title	FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction; Stiolto Respimat is the first in its class to have exacerbation data in the product labeling
  Media name/outlet	PR Newswire
  Country	United States
  Date	10/11/18
  Persons	Antonio R Anzueto